May 12, 2014 — Breast tomosynthesis in the diagnostic workup for one- or two-view focal asymmetry detected at screening mammography resulted in less use of ultrasound, fewer biopsies and higher positive predictive value for cancer than when diagnostic exams involved only 2-D mammography, according to a study conducted at the University of Virginia.

"Tomosynthesis has been evaluated in screening populations and been shown to decrease recall rates, but studies in the diagnostic setting are lacking," said researcher Brandi Nicholson, M.D., assistant professor of radiology at the University of Virginia.

In the study, 532 patients who were recalled for a focal asymmetric density discovered at screening were analyzed across three categories: women recalled prior to the availability of tomosynthesis in the practice (PT), those who did not have tomosynthesis at diagnostic evaluation after it was available (NT) and those who had diagnostic tomosynthesis (YT). There were 238 patients in the PT group, 145 in the NT group and 149 in the YT group.

The researchers found that additional full views and ultrasound were performed significantly less frequently in the YT group than in both the PT and NT groups. They also found that the PPV was increased for the YT group compared to both the PT and NT groups.

Nicholson presented the study at the 2014 annual meeting of the American Roentgen Ray Society (ARRS) in San Diego.

For more information: www.arrs.org


Related Content

News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
Subscribe Now